SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
congressional budget office
Trump's 'Golden Dome' Shield Exposed as 'Trillion-Dollar Boondoggle' by CBO
Sen. Jeff Merkley called the project “nothing more than a massive giveaway to defense contractors paid for entirely by working Americans.”
May 12, 2026
The Congressional Budget Office on Tuesday released a report estimating that President Donald Trump's proposed "Golden Dome" missile defense system would cost $1.2 trillion to create, deploy, and operate over the first 20 years of its existence.
The CBO report projects that acquisition costs for the proposed national missile defense (NMD) system would account for the vast majority of the $1.2 trillion total, including "costs for the system’s major components—namely, the interceptor layers and a space-based missile warning and tracking system."
In fact, the report says that the NMD system's space-based interceptor layer will be so expensive that it "accounts for about 70% of acquisition costs and 60% of total costs."
The CBO also questioned whether this massive investment would successfully protect the US from a foreign missile attack.
"Although the notional NMD system... would be far more capable than defenses the United States fields today," the report states, "it would not be an impenetrable shield or be able to fully counter a large attack of the sort that Russia or China might be able to launch."
"The strategic consequences of deploying an NMD system with the capacity considered here are unclear," the report continues, "because they hinge on an adversary’s perception of the defense's capability and how that adversary chose to respond."
The CBO's estimate on the missile system's cost was nearly seven times the projection Trump made last year, when he said it would cost just $175 billion.
And because the US Department of Defense still hasn't delivered key details about the proposed system, the CBO wrote, it is currently "impossible to estimate the long-term cost" of the initiative.
Sen. Jeff Merkley (D-Ore.), a longtime critic of the "Golden Dome" proposal, said the CBO report shows the Trump-backed project is "nothing more than a massive giveaway to defense contractors paid for entirely by working Americans."
"Just like the president’s symbolic renaming of the Department of Defense or deploying National Guard troops to our cities," added Merkley, who is the ranking member of the Senate Budget Committee, "this move to fund the ‘Golden Dome’ will be far more effective at squandering money than protecting American lives."
The Oregon Democrat vowed to "continue to work with my colleagues in the Senate to prevent another dime from flowing to this racket."
Sen. Ed Markey (D-Mass.), also a longtime critic of the president's proposed missile system, wrote in a social media post that "Trump’s Golden Dome is a $1.2 trillion golden sieve that won’t stop a nuclear attack, but will balloon the deficit and boost the bottom lines of billionaires."
Tommy Vietor, former National Security Council staffer under President Barack Obama and current co-host of Pod Save America, was even blunter in his criticism of the "Golden Dome" plan.
"$1.2 TRILLION for this dumb fucking Golden Dome missile defense system," he wrote in a social media post. "The initial estimate was $175 billion! Madness. No one wants this."
Daniel Larison, contributing editor at Antiwar.com and former senior editor at The American Conservative magazine, wrote that the CBO report exposed Trump's dome as a "trillion-dollar boondoggle."
Trump has said that he was inspired to develop such a missile system after being impressed by Israel’s “Iron Dome," despite the fact that Israel has a vastly smaller landmass to defend compared to the US and has historically faced far more danger from missile and rocket attacks.
Keep ReadingShow Less
House Republican Healthcare Plan Would Leave 100,000 More Uninsured Per Year: CBO
"It’s a raw deal for working people: higher costs and less coverage, or no coverage at all," said Democratic Rep. Brendan Boyle.
Dec 17, 2025
The Republican bill that's set for a vote in the US House on Wednesday would leave around 100,000 more Americans uninsured per year over the next decade, according to a new analysis by the nonpartisan Congressional Budget Office.
The analysis published late Tuesday examines each major section of the legislation, which experts have characterized as an assortment of GOP healthcare ideas that—in combination—would do little to achieve its stated goal of "lower healthcare premiums for all."
The CBO estimates that the Republican bill, which stands no chance of passing the Senate even if it clears the House on Wednesday, would lower gross benchmark premiums by 11% on average between 2027 and 2035.
But the legislation does not extend enhanced Affordable Care Act (ACA) subsidies that expire at the end of the year, meaning premiums overall are poised to more than double on average in the coming year. Many Americans are expected to forgo insurance coverage entirely in the face of unaffordable premium increases.
Rep. Brendan Boyle (D-Pa.), the top Democrat on the House Budget Committee, said Tuesday that the CBO analysis "makes clear that the bill Republican leadership wants to pass tomorrow would make a bad situation even worse," compounding the widespread damage caused by the Medicaid cuts the party approved over the summer.
"It’s a raw deal for working people: higher costs and less coverage, or no coverage at all," said Boyle. "If Republicans were serious about fixing the healthcare crisis they created, they’d work with Democrats to extend the Affordable Care Act tax credits and prevent costs from rising for tens of millions of Americans.”
"While Congress heads home for the holidays, it’s leaving millions of families behind to wonder how they will make ends meet in the new year."
The CBO analysis came hours after House Speaker Mike Johnson (R-La.) shot down a bipartisan push for a vote to extend the expiring ACA tax credits, which more than 20 million Americans relied on to afford health coverage.
But on Wednesday, four swing-district House Republicans—Brian Fitzpatrick, Rob Bresnahan, and Ryan Mackenzie of Pennsylvania and Mike Lawler of New York—revolted against the GOP leadership and signed onto a Democratic discharge petition aimed at forcing a floor vote on a proposed three-year extension of the enhanced ACA subsidies.
"The only policy that is worse than a clean three-year extension without any reforms, is a policy of complete expiration without any bridge," Fitzpatrick said in a statement. "Unfortunately, it is House leadership themselves that have forced this outcome."
It's unclear when the House will vote on the extension, as lawmakers are leaving town for a two-week holiday recess on Friday. The House is set to return to session on January 6, 2026—after the official expiration of the ACA subsidies.
“While Congress heads home for the holidays, it’s leaving millions of families behind to wonder how they will make ends meet in the new year,” Ailen Arreaza, executive director of the advocacy group ParentsTogether, said in a statement Wednesday. “By refusing to fix this healthcare crisis, Republicans are choosing political games over families’ health and financial security."
"These subsidies have been a lifeline for millions, and letting them expire will force millions to make impossible choices or even go without coverage altogether," said Arreaza. "Make no mistake: Families around the country will pay the price for Congress’ inaction."
Keep ReadingShow Less
Trump-GOP Giveaway to Big Pharma Will Hit Taxpayers With $9 Billion in Higher Drug Costs
"Donald Trump and Republicans are selling out America's seniors," said one advocate.
Oct 21, 2025
A major pharmaceutical industry handout that Republicans—with the support of one Senate Democrat—included in President Donald Trump's signature legislative package is expected to cost US taxpayers nearly twice as much as originally expected, the nonpartisan Congressional Budget Office said in an updated analysis released Monday.
The CBO initially projected that the provision, known as the ORPHAN Cures Act, would cost around $5 billion over the next decade. But the office said Monday that its earlier assessment did not take into account several major, high-priced drugs that will be exempted from Medicare price negotiations as a result of the Trump-GOP law.
The budget office said it now expects the provision of Trump's One Big Beautiful Bill Act to cost $8.8 billion over the next 10 years.
Among the drugs included in the new CBO analysis is Keytruda, a cancer medication sold by Merck that carries a list price of $24,062 every six weeks. The Trump GOP-budget law delays Keytruda's eligibility for Medicare price negotiations by at least a year, postponing significant potential savings for taxpayers and patients.
Merith Basey, executive director of Patients for Affordable Drugs Now, said in response to the updated CBO analysis that "the ORPHAN Cures Act is a wildly expensive handout to Big Pharma that will harm patients, drain taxpayer dollars, and weaken the government's ability to rein in high drug prices."
Basey noted that the "insatiable" pharmaceutical industry is not satisfied with the enactment of the ORPHAN Cures Act, which restricts Medicare price negotiations for drugs that treat more than one rare disease. Big Pharma, Basey said, is "spending record sums this year to advance additional carveouts like the EPIC Act, which would exempt even more blockbuster drugs from negotiation."
"Any support for these bills goes against the will of the 90% of Americans who want Congress to go further to lower drug prices—not facilitate another handout to Big Pharma," said Basey.
"This isn't about helping lower costs—it's about doing the bidding of big drug companies, and Trump and the GOP are all too happy to oblige."
The deep-pocketed pharmaceutical industry has waged war on the popular Medicare price negotiation program since its inception during the Biden administration.
While pharmaceutical giants' efforts to gut the program have been stymied in court, the industry-friendly Trump administration and Republican lawmakers have done pharma's bidding through legislation and executive action. Earlier this year, as Common Dreams reported, Trump signed an executive order aimed at delaying price negotiations for a broad category of medications despite the president's repeated promises to bring down costs.
"Trump and Republicans are selling out America's seniors," said Brad Woodhouse, president of the advocacy group Protect Our Care. "Instead of letting Medicare negotiate lower prices for more drugs, they carved out a loophole to protect the industry's most profitable drugs."
"Not only does the GOP tax bill throw over 15 million Americans off their healthcare and hike costs for millions more, but it also forces older Americans to pay more for life-saving medicines while CEOs and billionaires line their pockets with more money than they know what to do with," Woodhouse continued. "This isn't about helping lower costs—it's about doing the bidding of big drug companies, and Trump and the GOP are all too happy to oblige."
Steve Knievel, access to medicines advocate at Public Citizen, said Monday that "instead of transferring $10 billion from taxpayers and cancer patients to drug corporations that are already extremely profitable, President Trump and members of Congress must work to strengthen and expand Medicare drug price negotiations."
"Instead of gutting the law through bills like the ORPHAN Cures Act, EPIC Act, and MINI Act so Big Pharma can block negotiations on blockbuster treatments," Knievel added, "Congress should pass legislation to empower Medicare to negotiate lower drug prices on all costly medicines and allow all patients to access lower, negotiated prices, even if they don't have Medicare."
Keep ReadingShow Less
Most Popular